|
시장보고서
상품코드
1762491
세계의 파제타(Perjeta) 시장 : 시장 규모, 점유율 및 동향, 업계 분석(유형별, 제품별, 적응증별, 유통 채널별, 지역별), 예측(2025-2034년)Perjeta Market Size, Share, & Industry Analysis Report: By Type, By Product (Monoclonal Antibody and Generic Drug), By Indication, By Distribution Channel, and By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면, Perjeta 시장 규모는 2034년까지 71억 3,000만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.
퍼제타는 암세포의 신호전달 경로를 파괴하는 HER2 표적 단일클론항체 치료제로, 초맞춤형 의료로의 전환이 진행됨에 따라 종양학 시장에서 지속적으로 성장하고 있습니다. 이러한 추세는 개별 종양 프로파일에 맞는 생물학적 제제의 사용을 강조하고 있으며, 퍼제타는 HER2 양성 치료 요법에서 중요한 요소로 자리 잡고 있습니다. 퍼제타가 제공하는 고정밀 타겟팅은 전신 독성을 최소화하면서 치료 효과를 높이고 환자별 맞춤 암 치료를 지향하는 광범위한 움직임과 일치합니다. 치료 패러다임이 진화함에 따라 의료진은 분자적 정밀도와 측정 가능한 임상 결과를 제공하는 치료법을 점점 더 우선순위에 두고 있습니다.
치료 효과를 최적화하기 위한 병용요법의 통합이 증가하고 있는 것도 업계 성장의 기회로 작용하고 있습니다. 퍼제타는 일반적으로 트라스투주맙 및 화학요법과 병용투여하는 것이 일반적이며, 시너지 효과를 발휘하여 종합적인 HER2 양성 유방암 관리의 핵심요법으로 채택되고 있습니다. 이 병용 전략은 HER2 수용체 차단을 개선하고, 질병 진행의 위험을 감소시키며, 환자의 생존율 향상에 기여합니다. 임상에서 다제 병용요법에 대한 지속적인 검토는 견고하고 지속적인 반응을 보이는 진보된 치료법에 대한 수요를 강조하고 있으며, 이는 퍼제타가 현대 종양학 치료에서 중요한 역할을 하고 있음을 강조하고 있습니다.
파제타 시장 : 분석 개요
제품별로는 HER2 양성 유방암 치료에서 단일클론항체의 정확한 표적화 기전과 입증된 임상적 효과로 인해 단일클론항체 부문이 2024년 큰 매출 점유율을 차지했습니다.
판매 채널별로는 디지털 의료 솔루션에 대한 소비자의 선호도 변화와 전문 의약품에 대한 편리한 접근에 대한 수요 증가로 인해 온라인 약국 분야가 예측 기간 동안 가장 빠른 성장률을 나타낼 것으로 예측됩니다.
2024년 북미는 정교한 의료 시스템, 높은 질병 인식, 첨단 암 치료제의 폭넓은 가용성 등에 힘입어 업계 선두를 차지지했습니다.
아시아태평양의 퍼제타 시장은 건강 인식 증가, 암 감지 기술의 발전, 암 치료 시설에 대한 투자 확대 등을 배경으로 예측 기간 동안 가장 빠른 속도로 성장할 것으로 예측됩니다.
시장 주요 기업으로는 F. Hoffmann-La Roche Ltd., Biocon, Samsung Bioepis, Pfizer Inc., Genentech, Inc. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 분석 방법
제4장 세계의 파제타 시장 인사이트
- 시장 현황
- 파제타 시장 역학
- 성장 촉진요인과 기회
- 성장 억제요인과 과제
- PESTLE 분석
- 파제타 시장 동향
- 밸류체인 분석
제5장 세계의 파제타 시장 : 제품별
- 주요 분석 결과
- 서론
- 단일클론항체
- 제네릭 의약품
제6장 세계의 파제타 시장 : 적응증별
- 주요 분석 결과
- 서론
- 조기 유방암
- 전이성 유방암
제7장 세계의 파제타 시장 : 유통 채널별
- 주요 분석 결과
- 서론
- 병원 약국
- 전문 약국
- 온라인 약국
제8장 세계의 파제타 시장 : 지역별
- 주요 분석 결과
- 서론
- 파제타 시장 분석 : 지역별(2020-2034년)
- 북미
- 북미 : 제품별(2020-2034년)
- 북미 : 적응증별(2020-2034년)
- 북미 : 유통 채널별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 제품별(2020-2034년)
- 유럽 : 적응증별(2020-2034년)
- 유럽 : 유통 채널별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품별(2020-2034년)
- 아시아태평양 : 적응증별(2020-2034년)
- 아시아태평양 : 유통 채널별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품별(2020-2034년)
- 중동 및 아프리카 : 적응증별(2020-2034년)
- 중동 및 아프리카 : 유통 채널별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품별(2020-2034년)
- 라틴아메리카 : 적응증별(2020-2034년)
- 라틴아메리카 : 유통 채널별, 2020년-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 사업 확대 및 기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- F. Hoffmann-La Roche Ltd
- Biocon
- Samsung Bioepis.
- Pfizer Inc.
- Genentech, Inc.
- Dr. Reddy's Laboratories Ltd.
- CELLTRION INC.
The perjeta market size is expected to reach USD 7.13 billion by 2034, according to a new study by Polaris Market Research. The report "Perjeta Market Share, Size, & Industry Analysis Report: By Type, By Product (Monoclonal Antibody and Generic Drug), By Indication, By Distribution Channel, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Perjeta is a HER2-targeted monoclonal antibody therapy that disrupts cancer cell signaling pathways, with a continuation to gain momentum in the oncology market amid a growing shift toward hyper personalized medicine. This trend highlights the use of biologic therapies tailored to individual tumor profiles, making Perjeta a critical component in HER2-positive treatment regimens. The precision targeting offered by Perjeta improves therapeutic efficacy while minimizing systemic toxicity, aligning with the broader movement toward customized, patient-specific cancer care. Healthcare providers are increasingly prioritizing therapies that offer molecular precision and measurable clinical outcomes as treatment paradigms evolve.
The increasing integration of combination therapies to optimize treatment effectiveness contributes to industry growth opportunities. Perjeta, commonly administered alongside trastuzumab and chemotherapy, has demonstrated synergistic benefits, driving its adoption as a cornerstone in comprehensive HER2-positive breast cancer management. This combination strategy improves the blockade of HER2 receptors and reduces disease progression risks, contributing to improved patient survival. The continued exploration of multi-agent regimens in clinical practice highlights the demand for advanced therapies that deliver robust, durable responses, reinforcing Perjeta's relevance in contemporary oncologic care.
Perjeta Market Report Highlights
In terms of product, the monoclonal antibodies segment accounted for a larger revenue share in 2024, owing to their precise targeting mechanism and demonstrated clinical effectiveness in HER2-positive breast cancer treatment.
Based on distribution channel, the online pharmacies segment is anticipated to register the fastest growth rate during the forecast period, driven by evolving consumer preferences toward digital healthcare solutions and the rising demand for convenient access to specialized medications.
In 2024, North America held the leading position in the industry, supported by its sophisticated healthcare systems, strong disease awareness, and broad availability of advanced cancer treatments.
The Asia Pacific Perjeta market is expected to expand at the most rapid pace during the forecast period, driven by increasing health consciousness, advancements in cancer detection technologies, and expanding investments in cancer care facilities.
A few global key market players include F. Hoffmann-La Roche Ltd; Biocon; Samsung Bioepis; Pfizer Inc.; Genentech, Inc.; Dr. Reddy's Laboratories Ltd.; and CELLTRION INC.
Polaris Market Research has segmented the Perjeta market report on the basis of type, application, end use, and region:
By Product Outlook (Revenue, USD Billion, 2020-2034)
Monoclonal Antibody
Generic Drug
By Indication Outlook (Revenue, USD Billion, 2020-2034)
Early Breast Cancer
Metastatic Breast Cancer
By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)
Hospital Pharmacies
Specialty Pharmacies
Online Pharmacies
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Perjeta Market Insights
- 4.1. Perjeta Market - Market Snapshot
- 4.2. Perjeta Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Chronic Diseases
- 4.2.1.2. Rapidly Growing Geriatric Population
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of Skilled Labors
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Perjeta Market Trends
- 4.6. Value Chain Analysis
5. Global Perjeta Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Perjeta Market, by Product, 2020-2034 (USD billion)
- 5.3. Monoclonal Antibody
- 5.3.1. Global Perjeta Market, by Monoclonal Antibody, by Region, 2020-2034 (USD billion)
- 5.4. Generic Drug
- 5.4.1. Global Perjeta Market, by Generic Drug, by Region, 2020-2034 (USD billion)
6. Global Perjeta Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Perjeta Market, by Indication, 2020-2034 (USD billion)
- 6.3. Early Breast Cancer
- 6.3.1. Global Perjeta Market, by Early Breast Cancer, by Region, 2020-2034 (USD billion)
- 6.4. Metastatic Breast Cancer
- 6.4.1. Global Perjeta Market, by Metastatic Breast Cancer, by Region, 2020-2034 (USD billion)
7. Global Perjeta Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Perjeta Market, by Hospital Pharmacies, by Region, 2020-2034 (USD billion)
- 7.4. Specialty Pharmacies
- 7.4.1. Global Perjeta Market, by Specialty Pharmacies, by Region, 2020-2034 (USD billion)
- 7.5. Online Pharmacies
- 7.5.1. Global Perjeta Market, by Online Pharmacies, by Region, 2020-2034 (USD billion)
8. Global Perjeta Market, by Geography
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Perjeta Market Assessment, By Geography, 2020-2034 (USD billion)
- 8.3. Perjeta Market - North America
- 8.3.1. North America: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.3.2. North America: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.3.3. North America: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.3.4. Perjeta Market - U.S.
- 8.3.4.1. U.S.: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.3.4.2. U.S.: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.3.4.3. U.S.: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.3.5. Perjeta Market - Canada
- 8.3.5.1. Canada: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.3.5.2. Canada: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.3.5.3. Canada: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4. Perjeta Market - Europe
- 8.4.1. Europe: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.2. Europe: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.3. Europe: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.4. Perjeta Market - UK
- 8.4.4.1. UK: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.4.2. UK: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.4.3. UK: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.5. Perjeta Market - France
- 8.4.5.1. France: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.5.2. France: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.5.3. France: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.6. Perjeta Market - Germany
- 8.4.6.1. Germany: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.6.2. Germany: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.6.3. Germany: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.7. Perjeta Market - Italy
- 8.4.7.1. Italy: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.7.2. Italy: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.7.3. Italy: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.8. Perjeta Market - Spain
- 8.4.8.1. Spain: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.8.2. Spain: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.8.3. Spain: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.9. Perjeta Market - Netherlands
- 8.4.9.1. Netherlands: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.9.2. Netherlands: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.9.3. Netherlands: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.10. Perjeta Market - Russia
- 8.4.10.1. Russia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.10.2. Russia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.10.3. Russia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.4.11. Perjeta Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.4.11.2. Rest of Europe: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.4.11.3. Rest of Europe: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5. Perjeta Market - Asia Pacific
- 8.5.1. Asia Pacific: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.2. Asia Pacific: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.3. Asia Pacific: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.4. Perjeta Market - China
- 8.5.4.1. China: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.4.2. China: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.4.3. China: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.5. Perjeta Market - India
- 8.5.5.1. India: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.5.2. India: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.5.3. India: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.6. Perjeta Market - Malaysia
- 8.5.6.1. Malaysia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.6.2. Malaysia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.6.3. Malaysia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.7. Perjeta Market - Japan
- 8.5.7.1. Japan: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.7.2. Japan: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.7.3. Japan: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.8. Perjeta Market - Indonesia
- 8.5.8.1. Indonesia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.8.2. Indonesia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.8.3. Indonesia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.9. Perjeta Market - South Korea
- 8.5.9.1. South Korea: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.9.2. South Korea: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.9.3. South Korea: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.10. Perjeta Market - Australia
- 8.5.10.1. Australia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.10.2. Australia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.10.3. Australia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.5.11. Perjeta Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.5.11.2. Rest of Asia Pacific: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.5.11.3. Rest of Asia Pacific: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6. Perjeta Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.2. Middle East & Africa: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.3. Middle East & Africa: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.4. Perjeta Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.4.2. Saudi Arabia: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.4.3. Saudi Arabia: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.5. Perjeta Market - UAE
- 8.6.5.1. UAE: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.5.2. UAE: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.5.3. UAE: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.6. Perjeta Market - Israel
- 8.6.6.1. Israel: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.6.2. Israel: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.6.3. Israel: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.7. Perjeta Market - South Africa
- 8.6.7.1. South Africa: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.7.2. South Africa: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.7.3. South Africa: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.6.8. Perjeta Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.6.8.2. Rest of Middle East & Africa: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.6.8.3. Rest of Middle East & Africa: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7. Perjeta Market - Latin America
- 8.7.1. Latin America: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.2. Latin America: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.3. Latin America: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.4. Perjeta Market - Mexico
- 8.7.4.1. Mexico: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.4.2. Mexico: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.4.3. Mexico: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.5. Perjeta Market - Brazil
- 8.7.5.1. Brazil: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.5.2. Brazil: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.5.3. Brazil: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.6. Perjeta Market - Argentina
- 8.7.6.1. Argentina: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.6.2. Argentina: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.6.3. Argentina: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.7.7. Perjeta Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Perjeta Market, by Product, 2020-2034 (USD billion)
- 8.7.7.2. Rest of Latin America: Perjeta Market, by Indication, 2020-2034 (USD billion)
- 8.7.7.3. Rest of Latin America: Perjeta Market, by Distribution Channel, 2020-2034 (USD billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. F. Hoffmann-La Roche Ltd
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Biocon
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Samsung Bioepis.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Pfizer Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Genentech, Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Dr. Reddy's Laboratories Ltd.
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. CELLTRION INC.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
